Member Info for Soupdragon78

Good afternoon Yorkshireboy,

I'll try to be succinct in my response in my best Simon Armitage way, although its difficult to reduce the complexity down sometimes.

As on overarching position, I understand that you are looking at the timeline of the patents filings and issue which you have then cross referenced to the news from RNS.

Unfortunately I fear you may have not understood that Canadian government documents use the format YYYY-MM-DD, whereas your post (6 jul 22:33) works on the YYYY-DD-MM, therefore your timings are essentially wrong.

Ref: see national Standards Council of Canada for confirmation.
https://www.scc.ca/en/standardsdb/standards/4449

This would mean that the first patent #1 (CA 2846460) was issued prior to any deal with Ebers. So is not relevant as you thought as it is dated January, not September.

Furthermore, on the patents pages you link to, go to the documents tab for the patents and you can read each of the correspondence over time between the company and patents office. This shows that the work done since filing has been to ratify a number of the initial claims, not amend them to incorporate cannabinoids.

If you go through each patent you are interested in and open up the documents section, these show the process that has been gone through.

So, now we look at APREPITANT L-PROLINE.

We know that APREPITANT is sold under the brand name, Emend and that L_Proline is an amino acid part of proteins, so this shows that the cocrystal is formed of those.

Again the documents section identifies theses cocrystals and doesn't indicate any use of cannabinoids that would place it in the Ebers camp.

The Ebers deal does appear to be ticking along with work happening, but unfortunately I do not believe the patents you refer to relate to that work in particular. They may do in future, but not in the links you gave.

Enjoy the rest of the day.

Goup, I think Aberdeen man said something along the lines of DG leaving would have been planned for a long time so they would have a successor lined up.
Like you I’m keen that that person is in place ASAP if any negotiations are to progress.

Olderbutwiser, thanks for your posting, always a pleasure no matter how infrequent.

Good that you pointed out the q&a’s at the end as I didn’t get that far, so nice to see the response Fromm Thillai.

Interestingly it wasn't as helpful as I thought, Muhunthan starts out by stating that IPF and Covid are completely seperate and not related. IPF affects the airways and Covid affects the blood vessels.

Hey ho.

I've not listened to this yet (probably quite a specialist listen), but here is Muhunthan Thillai in a recent webinar about Covid and IPF.

https://channel.royalcast.com/chiesi/#!/chiesi/20200701_1

FRI in Covid-19 and IPF. Investigations of different diseases with the same technology
Dr. Muhunthan Thillai, Pulmonologist Papworth Hospital, Cambridge University,UK

Nice to see the company reads this board.

Quiet day I guess, probably just cleaning out the archives. Don’t want to get caught with any lost data.

Scary, you might want to check on Aim4, see if he’s ok. He’s closed his twitter account.

Looking at the Ebers deal. The original rns picked up that NFX do the early bit and then Ebers carry out the later clinical bits. I'm wondering what sort of timescale would be involved say from patent filing to testing?

Since DT has been made Chief Scientific Advisor from around Jan, I guess part of his role is to help coordinate Ebers side of the programme. So, given that first patent was filed in September last year (and it noted had immediate applications) I hope we start to see something soon from their side.

"Under the agreement, Nuformix will be responsible for early stage R&D activities and Ebers will be responsible for late-stage development, clinical programmes and commercialisation."

As its a quieter day I've been looking at the update Nuformix website.

They've removed the videos and podcasts off the homepage and now describe themselves as using a 'semi-virtual' business model for efficiency which I guess is fair enough.

Whilst they've updated the team page to remove Dan, they've forgotten to take him off the Investors Information page.

But good to see they've updated the shareholders list to the end of July. Interesting to see Higgins (Mr not Dr) is still there.

Hope I haven't 'ripped it apart'

I just wish that whoever keeps selling 200k+ first thing everyday would eff-off as that’s doing more damage to the sp than any posting on here.

Scaryone, ‘nobody cares’ really? Nobody cares about knowing what the company is doing?

Why do you say I shouldn’t correct someone’s post that is factually incorrect?

What’s the point of a forum if not to have these discussions?

As you can see I’ve said to YB that we shall have to disagree, unlike you I haven’t tried to silence another poster. Why do you want me to be quiet? Is it because it doesn’t suit your agenda to have someone correct something that isn’t the truth?

Do you think I should have been silent when others tried to say NXP002 was made up and didn’t exist? I didn’t see you coming to challenge that.

Maybe a bulletin board isn’t a place for a snowflake like you.

Ta very much yorkshireboy.

Unfortunately we’ll have to disagree.

Two points, look up what ’Aprepitant’ is and you’ll find it’s relating to NXP001 and nothing to do with Ebers.

On each of your links go all the way down to documents and open up each one relating to the patent. You’ll find the story in there. I’m sure you will have read them all.

Nothing relating to Ebers patents is available to the public, it usually takes about a year before the application can be viewed.

YOrkshireboy, for the ‘second patent’ reading through the amendments what actually appears to be the case is that the Canadian Patents examiner found a number of defects in the application of the patent.
These were listed in the correspondence from them in November 2018, the following amendments submitted by NFX were the corrections to the patent application which was subsequently passed in April this year. All tranilast related and nothing to do with Ebers.

Interesting post yorkshireboy, lots of words for a tyke. Must be something different to when I was growing up there.

One thing...your ‘second patent’ that achieved a milestone payment. How come NFX filed it in 2011?

Silverpixels, you might do better getting a response if you tell people your position before asking for theirs.

Goup, remember the time only a couple of weeks ago when you tried to tell us NXP002 didn't exist?

Is the telegram pump and dump group back up and running?

Didn’t they kick out Aim4 for being too negative?

The deadline for expressions of interest for the framework is next Monday. So will be a few weeks before anything is heard.

Ps. Scary, if you haven’t seen my research you wouldn’t have heard of the patent being published on 20th Feb, or Fleur Wood being employed as IR consultant, you wouldn’t know who ran Ebers, you wouldn’t be aware of Jo Holland filing cocrystal patents for Vectura.

Also you’d know that the link you posted was pointless as tranilast isn’t FDA approved.

Nuformix aren’t targeting fda approval and that’s not what bioavailability testing is about.